Home > Healthcare > Biotechnology > Biotechnology R&D > Autologous Cell Therapy Market
Autologous Cell Therapy Market Size
- Report ID: GMI6031
- Published Date: Jun 2023
- Report Format: PDF
Autologous Cell Therapy Market Size
Autologous Cell Therapy Market size valued at USD 12.9 billion in 2022 and is estimated to grow at 11.6% CAGR from 2023 to 2032. Rising prevalence of chronic disease coupled with growing demand for personalized treatment is expected to boost the market growth. For instance, in 2018, Food and Drug Administration (FDA) approved the CAR T-cell therapy tisagenlecleucel (Kymriah) for adults with certain types of non-Hodgkin lymphoma, a second CAR T-cell therapy approved for lymphoma. Thus, growing demand and adoption of personalized autologous cell therapies such as CAR-T is set to boost the market size.
Autologous cell therapy is a novel therapeutic approach that uses an individual’s cells, that are cultured and expanded outside the patient’s body and reintroduced into the donor. It involves the collection, isolation, and manipulation of cells from the patient's body, typically from sources such as blood, bone marrow, or adipose tissue. This personalized treatment approach offers several advantages, including a reduced risk of immune rejection or adverse reactions, as the cells used are a genetic match to the patient.
| Report Attribute | Details |
|---|---|
| Base Year: | 2022 |
| Autologous Cell Therapy Market Size in 2022: | USD 12.9 Billion |
| Forecast Period: | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR: | 11.6% |
| 2032 Value Projection: | USD 38 Billion |
| Historical Data for: | 2018 to 2022 |
| No. of Pages: | 150 |
| Tables, Charts & Figures: | 274 |
| Segments covered: | Therapy, Source, Application, End-use, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Frequently Asked Questions (FAQ) :
Autologous Cell Therapy Market Scope
